Recent Developments in Immuno-oncology: Biomarkers, Pan-tumor Studies, Novel Treatment Combinations, and the Management of Adverse Events Track 2: Biomarkers for Immunotherapies Across Tumor Type

Target Audience
This initiative is designed to meet the educational needs of oncologists, oncology pharmacists, oncology nurses, and other healthcare professionals and teams involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy.

Program Overview
This case-based enduring activity will cover the diagnosis, treatment, and management of patients with cancer who are treated or eligible for treatment with immunotherapy.

Learning Objectives
Upon completion of the program, attendees should be able to:

Review the clinical utility of currently identified immune-related biomarkers and the benefits and limitations of different immune biomarker testing methodologies
Incorporate immune-related biomarker testing to identify patients most likely to benefit from cancer immunotherapies administered alone or in combination
Describe immune-related biomarker-driven pan-tumor studies, their designs, and the implications of their results for patient management